Entera Bio Ltd 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Entera Bio Ltd 's ROA in the third quarter of 2026?
Entera Bio Ltd recorded a cumulative net loss of $-16 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -18.44%.

However, within the Healthcare sector 66 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 44, from total ROA ranking in the second quarter of 2026 at 70.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	1489.06 %	-2.79 %	-39.22 %	55.51 %	122.62 %
Y / Y Net Income Change	-	-	36.54 %	-	5.93 %
Net Income (TTM) in million	-16	2	12	11	6
Return On Assets (TTM)	-18.44 %	10 %	51.1 %	43.43 %	27.35 %
ENTX's Total Ranking	# 44	# 70	# 125	# 94	# 705
Total Assets (TTM) in million	277	19	13	47	17
Seq. Total Assets Change	1346.85 %	45.62 %	-71.87 %	168.16 %	-11.49 %
Seq. Net Income Change	-	-	16.21 %	-5.75 %	20.48 %

ENTX's 5 Years Annual ROA >> Back to ENTX Management Effectiveness >> Compare ENTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 15
Sector	# 67
Overall	# 364

Return On Assets Statistics
High	Average	Low
85.01 %	35.08 %	-39.6 %
(Mar 31 2024)		(Dec 31 2022)

Financial Statements
Entera Bio Ltd 's Assets	$ 277 million	ENTX's Balance sheet
Entera Bio Ltd 's Income	$ -16 million	Quarterly ENTX's Income Statement
ENTX's Income by Division		See ENTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	55.51 %	-4.83 %	1.31 %	-24.22 %	33.5 %
Total Assets in million	47	30	32	31	41
Y / Y Net Income Change	19.89 %	7.33 %	-31.99 %	7.25 %	-
Net Income in million	11	10	9	13	12
Annual Return On Assets	24.51 %	31.79 %	28.18 %	41.98 %	29.66 %

ENTX's 5 Years Annual ROA >> Back to ENTX Management Effectiveness >> Compare ENTX ROA to its Competitors

Comment on ENTX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA deteriorated to 24.51 %, despite annual net income growth of 19.89 % to $11.44 million, from $9.54 million a year ago, as ENTX's assets increase to $46.68 million, by 19.89 %.

More Return On Assets Ratios
ENTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ENTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ENTX's Competitors
Subscribers only: Roa for Entera Bio Ltd 's Suppliers
Subscribers only: Return On Assets for ENTX's Customers

You may also want to know
ENTX's Roi	ENTX's Inventory Turnover Ratio	ENTX's Growth Rates	ENTX's Dividend Comparisons
	ENTX's Profitability Ratios	ENTX's Asset Turnover Ratio	ENTX's Dividend Growth
ENTX's Roe	ENTX's Valuation Ratios	ENTX's Financial Strength Ratios	ENTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-07T09:45:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.